Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
The purpose of this study is to clarify the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitor in esophageal cancer chemotherapy. This study indicated that PARP inhibitors such as olaparib synergistically potentiates the sensitivity to anticancer drugs, especially DNA-damaging agents, in human esophageal cancer cell lines. In addition, the potentiation of sensitivity to anticancer drugs by olaparib was involved in cell signals related to p53-binding protein (53BP1).
|